JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 26.09 Billion KRW | -58.77% |
| 2022 | 63.27 Billion KRW | 52.23% |
| 2021 | 41.56 Billion KRW | 22.45% |
| 2020 | 33.94 Billion KRW | -2.59% |
| 2019 | 34.84 Billion KRW | -17.53% |
| 2018 | 42.25 Billion KRW | -29.67% |
| 2017 | 60.07 Billion KRW | -12.1% |
| 2016 | 68.35 Billion KRW | 2.4% |
| 2015 | 66.74 Billion KRW | 7.86% |
| 2014 | 61.88 Billion KRW | -2.85% |
| 2013 | 63.7 Billion KRW | -8.65% |
| 2012 | 69.73 Billion KRW | -11.91% |
| 2011 | 79.16 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 18.93 Billion KRW | -11.67% |
| 2024 Q1 | 21.43 Billion KRW | -17.85% |
| 2023 Q4 | 26.09 Billion KRW | -27.75% |
| 2023 Q3 | 36.1 Billion KRW | 30.33% |
| 2023 Q1 | 20.79 Billion KRW | -67.14% |
| 2023 FY | 26.09 Billion KRW | -58.77% |
| 2023 Q2 | 27.7 Billion KRW | 33.24% |
| 2022 Q1 | 51.2 Billion KRW | 23.19% |
| 2022 FY | 63.27 Billion KRW | 52.23% |
| 2022 Q2 | 39.8 Billion KRW | -22.25% |
| 2022 Q3 | 33.6 Billion KRW | -15.59% |
| 2022 Q4 | 63.27 Billion KRW | 88.29% |
| 2021 FY | 41.56 Billion KRW | 22.45% |
| 2021 Q1 | 36.1 Billion KRW | 6.37% |
| 2021 Q2 | 47.75 Billion KRW | 32.27% |
| 2021 Q3 | 46.7 Billion KRW | -2.2% |
| 2021 Q4 | 41.56 Billion KRW | -11.01% |
| 2020 FY | 33.94 Billion KRW | -2.59% |
| 2020 Q1 | 28.7 Billion KRW | -17.64% |
| 2020 Q2 | 69.45 Billion KRW | 142.01% |
| 2020 Q3 | 31.8 Billion KRW | -54.2% |
| 2020 Q4 | 33.94 Billion KRW | 6.72% |
| 2019 Q3 | 36.66 Billion KRW | -24.99% |
| 2019 Q1 | 42.14 Billion KRW | -0.24% |
| 2019 FY | 34.84 Billion KRW | -17.53% |
| 2019 Q4 | 34.84 Billion KRW | -4.95% |
| 2019 Q2 | 48.87 Billion KRW | 15.96% |
| 2018 Q3 | 55.61 Billion KRW | 8.92% |
| 2018 FY | 42.25 Billion KRW | -29.67% |
| 2018 Q4 | 42.25 Billion KRW | -24.02% |
| 2018 Q2 | 51.06 Billion KRW | -6.43% |
| 2018 Q1 | 54.56 Billion KRW | -9.17% |
| 2017 Q1 | 58.09 Billion KRW | -15.01% |
| 2017 Q2 | 57.11 Billion KRW | -1.69% |
| 2017 Q3 | 64.02 Billion KRW | 12.11% |
| 2017 Q4 | 60.07 Billion KRW | -6.17% |
| 2017 FY | 60.07 Billion KRW | -12.1% |
| 2016 FY | 68.35 Billion KRW | 2.4% |
| 2016 Q4 | 68.35 Billion KRW | 11.21% |
| 2016 Q3 | 61.46 Billion KRW | -11.52% |
| 2016 Q2 | 69.46 Billion KRW | 0.0% |
| 2015 Q4 | 66.74 Billion KRW | 0.0% |
| 2015 FY | 66.74 Billion KRW | 7.86% |
| 2014 FY | 61.88 Billion KRW | -2.85% |
| 2013 FY | 63.7 Billion KRW | -8.65% |
| 2012 FY | 69.73 Billion KRW | -11.91% |
| 2011 FY | 79.16 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -196.409% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 95.439% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 91.607% |
| HANDOK Inc. | 283.45 Billion KRW | 90.795% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -29.984% |
| Yuhan Corporation | -69.18 Billion KRW | 137.711% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 86.548% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 807.868% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 94.962% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 180.448% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 65.523% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 29.173% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 68.383% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -3.912% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -196.409% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 116.322% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 87.016% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 84.737% |
| JW Holdings Corporation | 480.68 Billion KRW | 94.572% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 84.147% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -22098.909% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.099% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -1009.62% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -13.431% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 85.089% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 49.801% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -196.409% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 83.518% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 92.716% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.099% |
| Yuhan Corporation | -69.18 Billion KRW | 137.711% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 80.814% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 56.278% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 93.92% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.099% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 77.554% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -58.846% |
| CKD Bio Corp. | 143.29 Billion KRW | 81.792% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 77.521% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 208.432% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 158.324% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -1009.62% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 93.83% |
| Boryung Corporation | 187.72 Billion KRW | 86.102% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 136.318% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 65.523% |